Evidence map›Paper›PMID 39503236›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Clinical and Radiological Features of Atypical Adrenal Masses-A Multicenter Retrospective Study.

Vania Balderrama-Brondani, Ruaa Al-Ward, Katja Kiseljak-Vassiliades, Lauren Fishbein, Danielle Dawes, Oksana Hamidi, Reza Pishdad, Juan Pablo Perdomo Rodriguez, Mohamad Anas Sukkari, Joseph R Grajo and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vania Balderrama-BrondaniDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9327-9615
Ruaa Al-WardDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Katja Kiseljak-VassiliadesDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Colorado, Aurora, CO 80045, USA.ORCID 0000-0003-3341-582X
Lauren FishbeinDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Colorado, Aurora, CO 80045, USA.ORCID 0000-0002-8151-5107
Danielle DawesDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Colorado, Aurora, CO 80045, USA.
Oksana HamidiDivision of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-7367-3885
Reza PishdadDepartment of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD 21218, USA.
Juan Pablo Perdomo RodriguezDivision of Endocrinology, Diabetes and Metabolism, University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, FL 32608, USA.
Mohamad Anas SukkariDivision of Endocrinology, Diabetes and Metabolism, University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, FL 32608, USA.
Joseph R GrajoDepartment of Radiology, Division of Abdominal Imaging, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Hans Kumar GhayeeDivision of Endocrinology, Diabetes and Metabolism, University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, FL 32608, USA.
Sara BedroseSection of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA.
Roland L BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Amir H HamrahianDepartment of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD 21218, USA.
Mouhammed Amir HabraDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4148-9637

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

contextThe natural history and malignant potential of cases classified as atypical adrenal masses (AAMs) are unknown.

objectiveTo describe the radiological characteristics and clinical outcomes of AAMs. DESIGN AND

participantsA multicenter retrospective study. Patients ≥18 years old with AAMs [diameter of 10-39 mm on first imaging study and pre-contrast attenuation of >10 Hounsfield units (HU) on computed tomography] were studied. We excluded adrenal metastasis, pheochromocytoma, sarcoma, lymphoma, infiltrative lesions, and adrenal hemorrhage, as well as patients with genetic predisposition to adrenal neoplasms. Data are presented as percentages and median values with interquartile ranges (IQRs).

resultsWe included 217 patients with 224 adrenal masses (61.3% women); the median age was 58 years (IQR 49-65 years). The median size was 20.5 mm (IQR 15-27 mm), with a median precontrast attenuation of 23.5 HU (IQR 17-30 HU). The median AAM growth rate was 0.3 mm/year (IQR 0-1.8 mm/year). Seventy-one masses (31.7%) underwent pathological evaluation. Adrenal adenoma (n = 38; 17%) and adrenocortical carcinoma (ACC) (n = 25; 11.2%) were the 2 most common diagnoses. For the adenomas, the growth rate was 0.3 mm/year (IQR 0-2.3 mm/year) and for ACCs, the growth rate was 12.9 mm/year (IQR 3.5-22 mm/year). The absolute contrast washout was >60% in 5 out of 7 (71.4%) ACC cases. The best growth rate cutoff for predicting malignancy was 2.68 mm/year (area under the curve 0.939; sensitivity 87.5%, specificity 88.8%).

conclusionAAMs carry significant malignant potential, and long-term follow-up is warranted when surgery is not pursued. Contrast washout is not reliable in predicting malignant potential of AAMs.

Indexed as

Adrenal Gland NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTomography, X-Ray Computedadrenal adenomaadrenal incidentalomaadrenal lesionatypical adrenal massindeterminate adrenal masslipid-poor adenoma

Identifiers

PMID39503236
PMCPMC13032007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.